Health
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
NEW YORK, October 13, 2025--Pfizer Inc. (NYSE: PFE, "Pfizer") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/afacb10b442bb52a20fbe9b362b1c835"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lr5osSx1tTSTY2JN2hYObg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/afacb10b442bb52a20fbe9b362b1c835","width":480,"height":212}},"lazy":false},{"type":"text","content":"NEW YORK, October 13, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, "Pfizer") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.","length":377,"tagName":"p"},{"type":"text","content":""IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoing battle against infectious diseases," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. "At Pfizer, we continue to prioritize innovation and rigorous data generation through clinical studies and real-world analysis supporting the vaccines and therapeutics for our infectious disease pipeline."","length":503,"tagName":"p"},{"type":"text","content":"Presentations will include research from Pfizer’s diverse infectious disease portfolio, including COVID-19, respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, meningococcal disease, and other serious bacterial and viral infections. Details for the oral and poster presentations are below:","length":308,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"border-top:solid black 1.0pt;border-bottom:solid black 1.0pt;border-left:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;vertical-align:bottom;width:56%;","val":[{"type":"text","content":"Title/Abstract Number","length":21,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"border-top:solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;vertical-align:bottom;wi...